Full Press Release Details
Coherus Provides Updates on Clinical Studies
Increases Enrollment in CHS-1701 Immunogenicity Study
Initiated Enrollment in CHS-1420 Phase 3 Study
REDWOOD CITY, Calif., September 3, 2015 Coherus BioSciences, Inc. (NASDAQ: CHRS), a leading pure-play, global biosimilars company with late-stage
clinical products, today provided updates on its clinical programs.
Coherus will hold a conference call on Thursday, September 3, at 5:00 p.m. ET.
Conference Call Information
Dial-in: (844) 452-6826
(domestic) or (765) 507-2587 (international)
Conference ID: 31690561
Webcast: http://investors.coherus.com
conference call at least 10 minutes early to register.
The webcast of the conference call will be available for replay through September 16, 2015.
About Coherus BioSciences, Inc.
pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded
biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with
world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical
products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit
Forward Looking Statements
extent that statements contained in this press release are not descriptions of historical facts regarding Coherus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the ability of Coherus to obtain regulatory approval from the FDA for CHS-1701, its ability to complete enrollment and dosing for its immunogenicity
study and submit a 351(k) (biosimilar) license application for CHS-1701 on its desired timelines; its ability to obtain topline data from its PK/PD study of CHS 1701 on its desired timeline; its ability to initiate a PK bioequivalence bridging study
with Phase 3 drug material and to submit a 351(k) (biosimilar) license application for CHS-1420 on its desired timelines; and its ability to obtain topline data for the psoriasis Phase 3 study and the rheumatoid arthritis study and to file an MAA in
the E.U. for CHS-0214 on its desired timelines. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the biosimilar development process, including the regulatory approval process, the timing of the actions of regulatory bodies and other
governmental authorities, clinical results, changes in laws and regulations, product quality or supply for our clinical material and patient safety. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the company s current and
future reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015.
Enbrel and Neulasta are registered
trademarks of Amgen Inc.
HUMIRA is a registered trademark of AbbVie Inc.
Coherus BioSciences, Inc.